Extracranial-intracranial Bypass Surgery for Symptomatic Chronic Middle Cerebral Artery Occlusion: the CMOSS-2 Trial

You may not qualify if:

• History of intracranial hemorrhage, subarachnoid hemorrhage, subdural hemorrhage, or extradural hemorrhage within 6 weeks;
• Unstable angina pectoris or myocardial infarction, congestive heart failure within 6 months;
• Women who are pregnant or lactating;
• Coagulation dysfunction or hemorrhagic tendency (e.g. INR \> 1.5 and/or platelet count \< 100,000 mcL);
• Other diseases with a life expectancy of less than 2 years
• Previous treatment with EC-IC bypass surgery
• Known allergy or contraindication to aspirin or clopidogrel or other antiplatelet drugs.
• Known cardiac conditions that may lead to cardiogenic embolism: including prosthetic valves, infective endocarditis, left atrial or left ventricular thrombosis, atrial fibrillation, sick sinus node syndrome, atrial mucinous tumor or cardiomyopathy, ejection fraction \<25%;
• Allergy to iodine or x-ray contrast, blood creatinine \> 3.0 mg/dl or other contraindications to arteriography
• Uncontrolled diabetes mellitus with fasting blood sugar (FBS) \>16.7 mmol/L
• Uncontrolled hypertension with a sitting systolic blood pressure \>180 mmHg or a sitting diastolic blood pressure \>110 mmHg;
• Persistent worsening of neurological symptoms within 72 hours;
• Severe liver dysfunction, defined as serum alanine transaminase (ALT) and/or glutamic oxalacetic transaminase (AST) \> 3 times the upper limit of normal range;
• Active peptic ulcer disease;
• Having received a clinical trial drug or device within 30 days prior to screening, or being enrolled in another clinical trial;
• +1 more criteria